Ipratropium Bromide/Salbutamol Neutec (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑induced bronchoconstriction, while salbutamol activates β2‑adrenergic receptors, increasing cyclic AMP and relaxing airway smooth muscle. The dual mechanism produces additive bronchodilation, enhancing symptom control.

The prescribed dose is determined by the treating physician based on the patient’s clinical condition, severity of disease, and response to therapy. The prescriber will specify the number of inhalations and frequency according to approved labeling.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, providing the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before responding with pricing, availability, shipping details and import documentation.

Compared with single‑agent inhalers, the combination offers additive bronchodilation, potentially improving symptom control in patients who need both anticholinergic and β2‑agonist effects. It may reduce the need for multiple inhalers, but individual response and tolerance should be evaluated by the prescriber.

Store the inhaler at room temperature, below 25 °C, in its original packaging. Protect it from moisture, heat and direct sunlight to maintain product stability.

The medication is delivered via inhalation using a metered‑dose inhaler or nebulizer, as directed by the prescribing clinician. Patients should follow the inhalation technique instructions provided with the device to ensure optimal drug delivery.

Serious adverse events include paradoxical bronchospasm, angioedema, severe tachycardia or arrhythmias, and significant hypertension. Patients should seek immediate medical attention if they experience any of these reactions.

The product is contraindicated in individuals with known hypersensitivity to ipratropium, salbutamol, or any excipients in the formulation. It should also be avoided in patients with narrow‑angle glaucoma or urinary retention unless specifically advised by a physician.